Chong Kun Dang Pharmaceutical Corp. (KRX:185750)
South Korea · Delayed Price · Currency is KRW 91,000
-700 (-0.76%)
Mar 27, 2026, 3:19 PM KST
KRX:185750 Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 77,509 | 109,073 | 212,521 | 80,953 | 42,720 |
Depreciation & Amortization | 44,798 | 39,772 | 37,030 | 33,598 | 27,482 |
Loss (Gain) From Sale of Assets | -542.27 | -154 | -111.88 | -54.05 | -119.34 |
Asset Writedown & Restructuring Costs | 80.82 | 985.36 | 199.79 | 4,008 | - |
Loss (Gain) From Sale of Investments | -747.23 | 2,764 | -1,465 | 2,772 | 98.87 |
Loss (Gain) on Equity Investments | - | - | -798.36 | 460.38 | 603.47 |
Provision & Write-off of Bad Debts | -252.25 | 637.26 | 133.39 | 996.56 | -533.19 |
Other Operating Activities | 14,017 | -12,190 | 40,969 | 22,300 | 10,345 |
Change in Accounts Receivable | 1,402 | 3,509 | -20,947 | -45,316 | -18,267 |
Change in Inventory | -96,566 | -114,342 | -5,980 | -54,466 | -53,771 |
Change in Accounts Payable | 13,313 | 14,410 | 38,584 | 15,824 | -15,598 |
Change in Unearned Revenue | 1.83 | 18.55 | 1.14 | 0.16 | - |
Change in Other Net Operating Assets | 14,346 | 19,806 | 18,024 | 6,658 | 19,942 |
Operating Cash Flow | 67,359 | 64,289 | 318,160 | 67,734 | 12,904 |
Operating Cash Flow Growth | 4.78% | -79.79% | 369.72% | 424.92% | -87.63% |
Capital Expenditures | -140,917 | -38,474 | -41,218 | -44,898 | -48,243 |
Sale of Property, Plant & Equipment | 555.04 | 243.25 | 451.58 | 142.13 | 142.41 |
Sale (Purchase) of Intangibles | -38,215 | -27,483 | -27,588 | -8,166 | -3,591 |
Investment in Securities | -66,781 | 69,268 | -102,998 | -12,806 | -39,332 |
Other Investing Activities | 73.19 | 175.55 | 39.75 | 347.81 | 213.96 |
Investing Cash Flow | -245,284 | 3,731 | -171,313 | -65,380 | -90,809 |
Long-Term Debt Issued | 217,704 | 100,000 | 32,000 | - | 101,596 |
Long-Term Debt Repaid | -35,157 | -133,743 | -58,050 | -3,213 | -3,714 |
Net Debt Issued (Repaid) | 182,548 | -33,743 | -26,050 | -3,213 | 97,883 |
Repurchase of Common Stock | -1,770 | -16,008 | -6,025 | -1,888 | -1,935 |
Dividends Paid | -13,824 | -13,331 | -11,609 | -11,239 | -10,808 |
Other Financing Activities | 10.02 | -29.7 | -16.53 | - | -0 |
Financing Cash Flow | 166,964 | -63,112 | -43,700 | -16,340 | 85,139 |
Foreign Exchange Rate Adjustments | -1,272 | 3,915 | -917.57 | -410.12 | 920.1 |
Net Cash Flow | -12,234 | 8,824 | 102,229 | -14,396 | 8,154 |
Free Cash Flow | -73,558 | 25,815 | 276,942 | 22,836 | -35,339 |
Free Cash Flow Growth | - | -90.68% | 1112.74% | - | - |
Free Cash Flow Margin | -4.35% | 1.63% | 16.59% | 1.53% | -2.63% |
Free Cash Flow Per Share | -5525.42 | 1948.91 | 19821.04 | 1696.38 | -2578.75 |
Cash Interest Paid | 6,232 | 7,655 | 8,631 | 6,444 | 3,758 |
Cash Income Tax Paid | 23,787 | 34,868 | 11,812 | 15,561 | 51,688 |
Levered Free Cash Flow | -122,329 | -75,307 | 169,732 | -1,365 | -33,053 |
Unlevered Free Cash Flow | -118,142 | -70,108 | 175,526 | 2,914 | -30,534 |
Change in Working Capital | -67,504 | -76,599 | 29,682 | -77,299 | -67,694 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.